Cargando…
Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
BACKGROUND: Oral tacrolimus is a therapeutic agent for moderate to severe steroid-dependent or resistant ulcerative colitis (UC), but remission induction is difficult, and it is necessary to treat the patient while considering the next treatment. AIM: To examine serum albumin (Alb) level as a progno...
Autores principales: | Ishida, Natsuki, Miyazu, Takahiro, Tamura, Satoshi, Tani, Shinya, Yamade, Mihoko, Iwaizumi, Moriya, Hamaya, Yasushi, Osawa, Satoshi, Furuta, Takahisa, Sugimoto, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192282/ https://www.ncbi.nlm.nih.gov/pubmed/34168412 http://dx.doi.org/10.3748/wjg.v27.i22.3109 |
Ejemplares similares
-
Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2022) -
Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021) -
Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021) -
Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
por: Ishida, Natsuki, et al.
Publicado: (2021) -
C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)